Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.43
-0.1950-5.39%
Volume:158.09K
Turnover:547.32K
Market Cap:107.17M
PE:-0.83
High:3.58
Open:3.58
Low:3.41
Close:3.62
52wk High:49.25
52wk Low:3.41
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.71
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.49
PE(LYR):-1.20

Loading ...

Summit Therapeutics is Maintained at Equal-Weight by Barclays

Dow Jones
·
Oct 01

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire
·
Oct 01

Akari Therapeutics expands IP portfolio with PCT filing for ADC payload

TIPRANKS
·
Oct 01

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Dow Jones
·
Oct 01

Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer

TIPRANKS
·
Oct 01

Whitehawk Therapeutics Price Target Announced at $9.00/Share by Stifel

Dow Jones
·
Oct 01

Press Release: HLS Therapeutics Announces Board of Directors Changes

Dow Jones
·
Oct 01

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

GlobeNewswire
·
Oct 01

HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target

MT Newswires Live
·
Oct 01

Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target

MT Newswires Live
·
Oct 01

JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target

MT Newswires Live
·
Oct 01

Atossa Therapeutics Price Target Raised to $25.00/Share from $24.00 by Ascendiant Capital

Dow Jones
·
Oct 01

Spyre Therapeutics initiated with an Overweight at JPMorgan

TIPRANKS
·
Oct 01

Neurizon Therapeutics Names CEO; Shares Down 4%

MT Newswires Live
·
Oct 01

Chimeric Therapeutics Suspended as It Negotiates Creditor Deals and Board Restructure

TIPRANKS
·
Oct 01

Have Insiders Sold Cutia Therapeutics Shares Recently?

Simply Wall St.
·
Oct 01

TScan Therapeutics Announces Executive Departures Amid Reorganization

TIPRANKS
·
Oct 01

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency

TIPRANKS
·
Oct 01

Halozyme Therapeutics Adds James Daly to Board

TIPRANKS
·
Oct 01

Analyst Reiterates Buy on Quince Therapeutics, Maintaining Unchanged $98 Price Target Amid Advancing Pulmonary Pipeline

TIPRANKS
·
Oct 01